About Ensysce
Research Programs
Intellectual Property
Announcements
Related Studies
Contact Us
Recent Announcements
Single-walled carbon nanotubes provide a safe and effective means for delivery of siRNA
READ MORE
Nano In Cancer 2010 Presentation
Systemic delivery and antitumor activity of siRNA complexed with single walled carbon nanotubes.
READ MORE
8th Annual Nanotechnology and Sustainability Venture Forum
READ MORE
HomeAbout EnsysceContact Us
 
Recent Announcements
Single-walled carbon nanotubes provide a safe and effective means for delivery of siRNA

D. Lynn Kirkpatrick, Michelle Weiss, Olga Gliko, Anton Naumov, and R. Bruce Weisman.

Ensysce Biosciences. Inc., Houston, TX, Rice University, Houston, TX

READ FULL ARTICLE

Nano In Cancer 2010 Presentation

Systemic delivery and antitumor activity of siRNA complexed with single walled carbon nanotubes.
Authors: D. Lynn Kirkpatrick, Michelle K. Weiss, Robert Lemos, Geoffrey Bartholomeusz, Saunab Ghosh, R. Bruce Weisman. Ensysce Biosciences Inc., Houston, TX, University of Texas MD Anderson Cancer Center, Houston, TX, Rice University, Houston, TX.

READ FULL ARTICLE

Presentation Nov. 10, 2009

READ FULL ARTICLE

Safety of single-walled carbon nanotubes for delivery of siRNA

D. Lynn Kirkpatrick, Geoffrey Bartholomeusz, Michelle Weiss, Dmitri Tsyboulski, Saunab Ghosh, Anton Naumov, R. Bruce Weisman.
Ensysce Biosciences. Inc., Houston, TX, UT MD Anderson Cancer Center, Houston, TX, Rice University, Houston, TX

READ FULL ARTICLE

8th Annual Nanotechnology and Sustainability Venture Forum

Ensysce Biosciences to present at 8th Annual Nanotechnology and Sustainability Venture Forum

READ FULL ARTICLE

Jan 8, 2009 : "Nanotechnology: The Opportunity for Cancer Treatment"

Bob Gower to give Keynote Speech at Chemical Heritage Society's Joseph Priestly Society Symposium.

READ FULL ARTICLE

Jan 5, 2009: Ensysce Biosciences Inc. Appoints Dr. D. Lynn Kirkpatrick as President and CEO.

Houston, TX, Jan 5, 2009 - Ensysce Biosciences Inc. announced today the appointment of Dr. Lynn Kirkpatrick as President and CEO. Dr. Kirkpatrick has an extensive background in targeted small molecule cancer drug development, and has brought three agents from bench to bedside.

READ FULL ARTICLE

Copyright © 2011 Ensysce Biosciences Inc. All Rights Reserved
Home|About Ensysce|Contact Us
Research Programs|Intellectual Property|Announcements|Related Studies